Published in AIDS Weekly, September 22nd, 1997
Fewer patients taking Crixivan progressed to AIDS defining illnesses or death than patients taking therapy without Crixivan.
An article in the September 10, 1997 issue of The New England Journal of Medicine by Roy Gulick, M.D. and colleagues at the New York University School of Medicine/Bellevue Hospital reported results from the landmark 97 patient study in which triple therapy with Merck's protease inhibitor Crixivan first suppressed HIV levels to below the limit of detection of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.